The DOI matches its Crossref record; 1,217 of the 1,217 references it cites were found in a registry or an index.
Structure and dynamics of molecular networks: A novel paradigm of drug discovery
Open accessAbstract
Despite considerable progress in genome- and proteome-based high-throughput screening methods and in rational drug design, the increase in approved drugs in the past decade did not match the increase of drug development costs. Network description and analysis not only gives a systems-level understanding of drug action and disease complexity, but can also help to improve the efficiency of drug design. We give a comprehensive assessment of the analytical tools of network topology and dynamics. The state-of-the-art use of chemical similarity, protein structure, protein-protein interaction, signaling, genetic interaction and metabolic networks in the discovery of drug targets is summarized. We propose that network targeting follows two basic strategies. The “central hit strategy” selectively targets central node/edges of the flexible networks of infectious agents or cancer cells to kill them. The “network influence strategy” works against other diseases, where an efficient reconfiguration of rigid networks needs to be achieved. It is shown how network techniques can help in the identification of single-target, edgetic, multi-target and allo-network drug target candidates. We review the recent boom in network methods helping hit identification, lead selection optimizing drug efficacy, as well as minimizing side-effects and drug toxicity. Successful network-based drug development strategies are shown through the examples of infections, cancer, metabolic diseases, neurodegenerative diseases and aging. Summarizing >1200 references we suggest an optimized protocol of network-aided drug development, and provide a list of systems-level hallmarks of drug quality. Finally, we highlight network-related drug development trends helping to achieve these hallmarks by a cohesive, global approach.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Collective dynamics of ‘small-world’ networks
Watts, D. J., & Strogatz, S. H. (1998) · Nature · doi:10.1038/30918 · Cited by 43,060
Emergence of Scaling in Random Networks
Barabási, A.-L., & Albert, R. (1999) · Science · doi:10.1126/science.286.5439.509 · Cited by 36,135
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
An integrated encyclopedia of DNA elements in the human genome
The ENCODE Project Consortium (2012) · Nature · doi:10.1038/nature11247 · Cited by 18,072
Centrality in social networks conceptual clarification
Freeman, L. C. (1978) · Social Networks · doi:10.1016/0378-8733(78)90021-7 · Cited by 17,062
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y.-J., Jiang, Q., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,304
Community structure in social and biological networks
Girvan, M., & Newman, M. E. J. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122653799 · Cited by 15,502 · cited 1×
“Modules of molecular networks are formed from nodes, which are more densely connected with each other than with their neighborhood (Girvan & Newman, 2002; Fortunato, 2010; Kovács et al., 2010; Koch, 2012; Szalay-Bekő et al., 2012).”
BackgroundWarburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425 · cited 5×
“ew target-candidates. However, it should be kept in mind that key enzymes of cancer-specific metabolism, such as the PKM2 isoenzyme of pyruvate kinase playing a predominant role in the Warburg-effect (Warburg, 1956; Steták et al., 2007; Christofk et al., 2008; Kung et al., 2012), were also shown to play a direct role i…”
BackgroundInfluential
Cited by
Vital nodes identification in complex networks
Lü, L., Chen, D., Ren, X.-L., Zhang, Q.-M., Zhang, Y.-C., & Zhou, T. (2016) · Physics Reports · doi:10.1016/j.physrep.2016.06.007 · Cited by 1,183
The H-index of a network node and its relation to degree and coreness
Lü, L., Zhou, T., Zhang, Q.-M., & Stanley, H. E. (2016) · Nature Communications · doi:10.1038/ncomms10168 · Cited by 690
Network propagation: a universal amplifier of genetic associations
Cowen, L., Ideker, T., Raphael, B. J., & Sharan, R. (2017) · Nature Reviews Genetics · doi:10.1038/nrg.2017.38 · Cited by 657
DeepSynergy: predicting anti-cancer drug synergy with Deep Learning
Preuer, K., Lewis, R. P. I., Hochreiter, S., Bender, A., Bulusu, K. C., & Klambauer, G. (2018) · Bioinformatics · doi:10.1093/bioinformatics/btx806 · Cited by 653
Lipinski, C. A. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.029 · Cited by 609
Mostafavi, S., Gaiteri, C., Sullivan, S. E., White, C. C., Tasaki, S., Xu, J., Taga, M., Klein, H.-U., Patrick, E., Komashko, V., et al. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0154-9 · Cited by 509
The Role of Protein Loops and Linkers in Conformational Dynamics and Allostery
Papaleo, E., Saladino, G., Lambrughi, M., Lindorff-Larsen, K., Gervasio, F. L., & Nussinov, R. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00623 · Cited by 431
Self-citationCurrin, A., Swainston, N., Day, P. J., & Kell, D. B. (2015) · Chemical Society Reviews · doi:10.1039/c4cs00351a · Cited by 388
Talevi, A. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00205 · Cited by 381
Cheng, F., & Zhao, Z. (2014) · Journal of the American Medical Informatics Association · doi:10.1136/amiajnl-2013-002512 · Cited by 374
Structure and dynamics of core/periphery networks
Csermely, P., London, A., Wu, L.-Y., & Uzzi, B. (2013) · Journal of Complex Networks · doi:10.1093/comnet/cnt016 · Cited by 367
Self-citationNetwork‐based Approaches in Pharmacology
Boezio, B., Audouze, K., Ducrot, P., & Taboureau, O. (2017) · Molecular Informatics · doi:10.1002/minf.201700048 · Cited by 359
Synchronization in complex networks and its application – A survey of recent advances and challenges
Tang, Y., Qian, F., Gao, H., & Kurths, J. (2014) · Annual Reviews in Control · doi:10.1016/j.arcontrol.2014.09.003 · Cited by 358
Multi-target approach for natural products in inflammation
Koeberle, A., & Werz, O. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.08.006 · Cited by 317
Gaiteri, C., Ding, Y., French, B., Tseng, G. C., & Sibille, E. (2014) · Genes, Brain and Behavior · doi:10.1111/gbb.12106 · Cited by 289
The application of principal component analysis to drug discovery and biomedical data
Giuliani, A. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.01.005 · Cited by 287
DeepDDS: deep graph neural network with attention mechanism to predict synergistic drug combinations
Wang, J., Liu, X., Shen, S., Deng, L., & Liu, H. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbab390 · Cited by 261
Schlotter, F., Halu, A., Goto, S., Blaser, M. C., Body, S. C., Lee, L. H., Higashi, H., DeLaughter, D. M., Hutcheson, J. D., Vyas, P., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.032291 · Cited by 256
Identifying influential spreaders by gravity model
Li, Z., Ren, T., Ma, X., Liu, S., Zhang, Y., & Zhou, T. (2019) · Scientific Reports · doi:10.1038/s41598-019-44930-9 · Cited by 256
Agis-Torres, A., Sollhuber, M., Fernandez, M., & Sanchez-Montero, J. M. (2014) · Current Neuropharmacology · doi:10.2174/1570159x113116660047 · Cited by 202
“However, despite the new hopes for healing AD, and other neurodegenerative diseases, by drug combinations acting at different levels of the neurotoxic cascade, the researchers are endeavoring to go deeper than that, and ultimately have proposed a new paradigm, emerging from a new concept -therapeutic molecules acting…”
BackgroundDrug target prioritization by perturbed gene expression and network information
Isik, Z., Baldow, C., Cannistraci, C. V., & Schroeder, M. (2015) · Scientific Reports · doi:10.1038/srep17417 · Cited by 135
Taubes, A., Nova, P., Zalocusky, K. A., Kosti, I., Bicak, M., Zilberter, M. Y., Hao, Y., Yoon, S. Y., Oskotsky, T., Pineda, S., et al. (2021) · Nature Aging · doi:10.1038/s43587-021-00122-7 · Cited by 118
Gonzalez-Diaz, H., Arrasate, S., Gomez-SanJuan, A., Sotomayor, N., Lete, E., Besada-Porto, L., & Ruso, J. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026611313140011 · Cited by 101
“The construction of drug-target networks is of the highest importance for the discovery of drugs with direct effect and/or long-range network effect over different targets, like allo-network drugs [201-204].”
BackgroundGaiteri, C., Chen, M., Szymanski, B., Kuzmin, K., Xie, J., Lee, C., Blanche, T., Chaibub Neto, E., Huang, S.-C., Grabowski, T., et al. (2015) · Scientific Reports · doi:10.1038/srep16361 · Cited by 76
Verkhivker, G. M., Agajanian, S., Hu, G., & Tao, P. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00136 · Cited by 76
Allostery: Allosteric Cancer Drivers and Innovative Allosteric Drugs
Nussinov, R., Zhang, M., Maloney, R., Liu, Y., Tsai, C.-J., & Jang, H. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167569 · Cited by 66
Self-citationHigh-content phenotypic and pathway profiling to advance drug discovery in diseases of unmet need
Hughes, R. E., Elliott, R. J. R., Dawson, J. C., & Carragher, N. O. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.02.015 · Cited by 62
Allosteric Conformational Barcodes Direct Signaling in the Cell
Nussinov, R., Ma, B., Tsai, C.-J., & Csermely, P. (2013) · Structure · doi:10.1016/j.str.2013.06.002 · Cited by 55
“Dysfunctional conformational barcodes in disease states can be (partially) restored to their ''healthy'' barcode ensemble states by allosteric drugs (Csermely et al., 2013; Nussinov et al., 2011).”
Self-citationIn silico assessment of adverse drug reactions and associated mechanisms
Ivanov, S. M., Lagunin, A. A., & Poroikov, V. V. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2015.07.018 · Cited by 49
A deep learning-based method for the prediction of DNA interacting residues in a protein
Patiyal, S., Dhall, A., & Raghava, G. P. S. (2022) · Briefings in Bioinformatics · doi:10.1093/bib/bbac322 · Cited by 38
Dual Inhibitors of AChE and BACE-1 for Reducing Aβ in Alzheimer’s Disease: From In Silico to In Vivo
Stern, N., Gacs, A., Tátrai, E., Flachner, B., Hajdú, I., Dobi, K., Bágyi, I., Dormán, G., Lőrincz, Z., Cseh, S., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113098 · Cited by 35
“However, since BACE-1 has several substrates in addition to APP, which are not to be blocked [24], we suggest testing the effect of partial BACE-1 inhibition by weaker inhibitors, if obtained, which may be very effective despite their lower affinity to the target [23,25].”
BackgroundNetworks of Networks: An Essay on Multi-Level Biological Organization
Uversky, V. N., & Giuliani, A. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.706260 · Cited by 28
Formatting biological big data for modern machine learning in drug discovery
Duran‐Frigola, M., Fernández‐Torras, A., Bertoni, M., & Aloy, P. (2019) · WIREs Computational Molecular Science · doi:10.1002/wcms.1408 · Cited by 25
Malaney, P., Uversky, V. N., & Davé, V. (2015) · Methods · doi:10.1016/j.ymeth.2014.10.005 · Cited by 18
Metadata
- Authors
- Csermely, P., Korcsmáros, T., Kiss, H. J. M., London, G., & Nussinov, R.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2013-06
- Volume
- 138
- Issue
- 3
- Pages
- 333-408
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2140239055
- Cited by
- 892
- References
- 1,217
- FWCI
- 107.99
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.